dc.creator | León González, Antonio José | es |
dc.creator | Jiménez Vacas, Juan M. | es |
dc.creator | Fuentes Fayos, Antonio C. | es |
dc.creator | Sarmento Cabral, André | es |
dc.creator | Herrera Martínez, Aura D. | es |
dc.creator | Gahete, Manuel D. | es |
dc.creator | Luque, Raúl M. | es |
dc.date.accessioned | 2022-03-23T10:40:35Z | |
dc.date.available | 2022-03-23T10:40:35Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | León González, A.J., Jiménez Vacas, J.M., Fuentes Fayos, A.C., Sarmento Cabral, A., Herrera Martínez, A.D., Gahete, M.D. y Luque, R.M. (2021). Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers. Current Opinion in Pharmacology, 60, 17-26. | |
dc.identifier.issn | 1471-4892 | es |
dc.identifier.issn | 1471-4973 | es |
dc.identifier.uri | https://hdl.handle.net/11441/131175 | |
dc.description.abstract | Metabolic syndrome is associated with chronic diseases, including type 2 diabetes, cardiovascular diseases, and cancer. This review summarizes the current evidence on the antitumor effects of some relevant drugs currently used to manage metabolic-related pathologies (i.e. insulin and its analogs, metformin, statins, etc.) in endocrine-related cancers including breast cancer, prostate cancer, pituitary cancer, ovarian cancer, and neuroendocrine neoplasms. Although current evidence does not provide a clear antitumor role of several of these drugs, metformin seems to be a promising chemopreventive and adjuvant agent in cancer management, modulating tumor cell metabolism and microenvironment, through both AMP-activated protein kinase-dependent and -independent mechanisms. Moreover, its combination with statins might represent a promising therapeutic strategy to tackle the progression of endocrine-related tumors. However, further studies are needed to endorse the clinical relevance of these drugs as adjuvants for cancer chemotherapy. | es |
dc.description.sponsorship | Ministerio de Ciencia e Innovación de España. PID2019- 105564RB-I00/FPU16-05059 | es |
dc.description.sponsorship | Fondo Europeo de Desarrollo Regional (FEDER) y Fondo Social Europeo (FSE). PI20/01301 | es |
dc.description.sponsorship | Instituto de Salud Carlos III de España. SCIII-AES-2019/002525 | es |
dc.description.sponsorship | Junta de Andalucía. PI-0152-2019, PI-0094-2020, PI-0038/2019, RH-0084-2020 y BIO-0139 | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | Current Opinion in Pharmacology, 60, 17-26. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Cancer | es |
dc.subject | insulin | es |
dc.subject | metabolic syndrome | es |
dc.subject | metformin | es |
dc.subject | statins | es |
dc.title | Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.relation.projectID | PID2019- 105564RB-I00/FPU16-05059 | es |
dc.relation.projectID | PI20/01301 | es |
dc.relation.projectID | SCIII-AES-2019/002525 | es |
dc.relation.projectID | PI-0152-2019 | es |
dc.relation.projectID | PI-0094-2020 | es |
dc.relation.projectID | PI-0038/2019 | es |
dc.relation.projectID | RH-0084-2020 | es |
dc.relation.projectID | BIO-0139 | es |
dc.relation.publisherversion | https://doi.org/10.1016/j.coph.2021.06.002 | es |
dc.identifier.doi | 10.1016/j.coph.2021.06.002 | es |
dc.contributor.group | Universidad de Sevilla. BIO139: Endocrinología Celular y Molecular | es |
dc.journaltitle | Current Opinion in Pharmacology | es |
dc.publication.volumen | 60 | es |
dc.publication.initialPage | 17 | es |
dc.publication.endPage | 26 | es |
dc.contributor.funder | Ministerio de Ciencia e Innovación (MICIN). España | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |
dc.contributor.funder | Fondo Social Europeo (FSE). E.U. | es |
dc.contributor.funder | Instituto de Salud Carlos III. España | es |
dc.contributor.funder | Junta de Andalucía | es |